Sepsis Management: Current Guidelines (2026)

Definition (Sepsis-3, Still Current)

• Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection. Defined operationally as SOFA score increase ≥2 from baseline.
• Septic Shock: Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + serum lactate >2 mmol/L despite adequate fluid resuscitation (mortality >40%).
• qSOFA (quick bedside screen): Altered mentation + RR ≥22/min + SBP ≤100 mmHg - 2 of 3 = high risk.

The 2026 Surviving Sepsis Campaign (SSC) - Key Updates

1. Screening & Early Recognition

• Use validated tools (NEWS, qSOFA, SOFA) - routine procalcitonin is not recommended to start antibiotics, but may help decide when to stop them.
• 2 sets of blood cultures (aerobic + anaerobic) should be drawn before antibiotic initiation.
• Serial lactate measurement: obtain baseline; if >2 mmol/L, recheck in 2-4 hours to guide resuscitation adequacy.
• Target ICU admission within 6 hours of initial stabilization for critically ill patients.

2. Antimicrobial Therapy

Timing

• In bacterial septic shock, each 1-hour delay in appropriate antibiotics is associated with a 7-8% increase in mortality (Harrison's 22E).

Antibiotic Selection

• Undifferentiated sepsis (no Pseudomonas risk): 3rd-generation cephalosporin (ceftriaxone, cefotaxime)
• Pseudomonas risk: Cefepime, piperacillin-tazobactam, or carbapenem (imipenem/meropenem)
• Highly resistant GNR risk (prior colonization/infection): Two empiric gram-negative agents
• MRSA risk (healthcare-associated, hospital-onset): Add vancomycin or linezolid
• Antifungal: Empiric echinocandin only in high-risk patients (recent abdominal surgery, TPN, liver failure, diabetes, multi-site Candida colonization) - not routine
• Antivirals: Remdesivir for SARS-CoV-2 sepsis; oseltamivir for influenza sepsis

Optimization

• Administer beta-lactams before vancomycin when combining
• Consider prolonged beta-lactam infusion after initial bolus to optimize PK/PD
• De-escalate based on culture results; discontinue if infection is ruled out

3. Fluid Resuscitation

• Fluid responsiveness should be assessed before each additional bolus (pulse pressure variation, passive leg raise, etc.).

4. Vasopressors & Hemodynamic Support

• MAP target: ≥65 mmHg (individualize upward in chronic hypertensives)
• Peripheral IV initiation of vasopressors is now supported to avoid delay from central access (safe <6 hours with monitoring)

5. Corticosteroids

• Hydrocortisone recommended if shock persists despite adequate fluids + vasopressors
• Dose: 50 mg IV every 6 hours OR 200 mg/day continuous infusion
• Supported by meta-analyses showing shorter shock duration (not clear mortality benefit)

6. Respiratory Support

• Targeting supranormal oxygen delivery is not recommended.
• Hemoglobin target: 7-9 g/dL (absent tissue hypoperfusion, CAD, or acute hemorrhage)

7. Source Control

• A comprehensive search for the infection source is mandatory in all sepsis patients.
• Perform source control as rapidly as possible (drainage of abscesses, debridement of necrotic tissue, removal of infected devices, surgical repair of perforations).
• Without source control, antimicrobial therapy is significantly less effective. - Fischer's Mastery of Surgery 8e

8. ICU Bundles (CMS SEP-1 Compatible 1-Hour Bundle)

1. Measure lactate (recheck if >2 mmol/L)
2. Obtain blood cultures
3. Administer broad-spectrum antibiotics
4. Begin 30 mL/kg crystalloid bolus (if hypotensive or lactate >4 mmol/L)
5. Start vasopressors (if hypotensive during/after fluids) - MAP target ≥65 mmHg

9. Additional ICU Management

• Glycemic control: Target blood glucose 140-180 mg/dL with insulin protocol
• DVT prophylaxis: Pharmacologic preferred unless contraindicated
• Stress ulcer prophylaxis: In patients with risk factors
• Sedation/analgesia: Use validated protocols; daily sedation interruption if on continuous infusion
• Early mobility: As part of the ABCDEF bundle (Awakening, Breathing, Coordination, Delirium, Early Mobility, Family engagement)
• Renal replacement therapy: Initiate for AKI with life-threatening indications (hyperkalemia, acidosis, fluid overload, uremia)
• Nutrition: Early enteral nutrition preferred; avoid parenteral nutrition in first 7 days if enteral tolerated

10. Pediatric Sepsis (SSC 2026 Pediatric Guidelines - PMID 41869844)

• Fluid resuscitation: 10-20 mL/kg boluses with frequent reassessment (avoid 30 mL/kg fixed-volume approach)
• Vasopressors: Dopamine is no longer first-line; epinephrine or norepinephrine preferred
• 20 new statements added vs. 2020 pediatric guidelines
• Low overall quality of evidence acknowledged for most recommendations

What's New in 2026 vs. 2021

Recent Evidence Highlights

• S3 German Guideline Update 2025 (PMID 40824313): 29 new + 16 revised recommendations; emphasis on individualized early treatment, structured follow-up post-discharge, and patient-centered care beyond acute phase.
• Sepsis alert systems meta-analysis (PMID 39037814, JAMA Netw Open 2024): Automated sepsis alert systems in EDs associated with improved adherence to bundles and reduced mortality.
• SSC 2026 Pediatric Guidelines (PMID 41869844): Comprehensive update with 61 statements, acknowledging most evidence remains low-to-moderate quality.